Precigen saw the highest growth of 6.99% in patent filings and 2.66% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and grants by 0.74%. GlobalData’s DataBook provides a comprehensive analysis of Precigen‘s patent filings and grants. Buy the databook here.
Precigen has been focused on protecting inventions in United States(US) with nine publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 30% filings and 43% grants. The United States(US), Australia(AU), China(CN), and Israel(IL) patent Office are among the top ten patent offices where Precigen is filings its patents. Among the top granted patent authorities, Precigen has 43% of its grants in United States(US), 14% in Australia(AU) and 14% in Canada(CA).
Roche and Johnson & Johnson could be the strongest competitors for Precigen
Patents related to rare diseases and climate change lead Precigen's portfolio
Precigen has the highest number of patents in rare diseases followed by, climate change and emissions reduction. For rare diseases, nearly 100% of patents were filed and 15% of patents were granted in Q2 2024.
Breast cancer related patents lead Precigen portfolio followed by ovarian cancer, and tuberculosis
Precigen has highest number of patents in breast cancer followed by ovarian cancer, tuberculosis, biodiesel, and refining. For breast cancer, nearly 4% of patents were filed and 6% of patents were granted in Q2 2024.
For comprehensive analysis of Precigen's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.